Citigroup Maintains Buy on Zenas BioPharma, Raises Price Target to $48

Citigroup analyst Yigal Nochomovitz has maintained a Buy rating on Zenas BioPharma (NASDAQ: ZBIO) and increased the price target from $41 to $48. This adjustment reflects a positive outlook on the company's performance.